NOTE PURCHASE AGREEMENTNote Purchase Agreement • May 14th, 2024 • Mosaic ImmunoEngineering Inc. • Biological products, (no disgnostic substances) • Delaware
THIS NOTE PURCHASE AGREEMENT (“Agreement”) is made as of May 8, 2024 by and among Mosaic ImmunoEngineering, Inc, a Delaware corporation (“Company”), and Oncotelic Therapeutics, Inc. (f/k/a Mateon Therapeutics, Inc. and now the “Lender”). Capitalized terms used but not defined herein shall have the respective meanings ascribed to such terms in the Notes (as defined below).
